Janssen Biotech Inc.
Horsham, PA Doing business as Centocor Ortho Biotech Inc.
- UEI
- NVYMGFA53MN7
- CAGE
- 0MJM1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Janssen Biotech Inc.
NVYMGFA53MN7
- Actelion Pharmaceuticals US, Inc. H5BMHLMMNA28
- Janssen Products, LP Z1TQMKVX5MD4
-
Janssen Biotech Inc.
NVYMGFA53MN7
- SAM.gov registration date
- Physical address
- 800 Ridgeview Drive, Horsham, PA 19044, USA
- Website
- jnj.com
- Founded
- 1886
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Emergency pharmacy carvykti for RMR | Veterans Integrated Service Network 19 | $384,719 | |
| Balversa 4 MG | Veterans Integrated Service Network 5 | $20,500 | |
| Emergency pharmacy carvykti for RMR | Veterans Integrated Service Network 19 | $384,719 | |
| Balversa 4 MG | Veterans Integrated Service Network 5 | $20,295 | |
| Pharmacy purchase | Veterans Integrated Service Network 19 | $0 |
About Janssen Biotech Inc.
Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., manufactures specialty oncology medications and biologic pharmaceuticals for the Department of Veterans Affairs as a prime contractor on full-and-open federal supply schedule and blanket purchase agreement vehicles, with no set-aside designations. The company is a for-profit subsidiary of Johnson & Johnson headquartered in Horsham, Pennsylvania, and competes exclusively in the commercial pharmaceutical market without SBA certifications.
Janssen Biotech's federal footprint concentrates entirely on the Veterans Health Administration, which accounts for all 107 recent prime awards. The vendor supplies three core oncology medications—BALVERSA (erdafitinib), CARVYKTI, and WELIREG (belzutifan)—through delivery orders issued against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and companion blanket purchase agreements. Recent representative delivery orders include a $20,295 firm fixed-price order from Veterans Integrated Service Network 5 on March 20, 2026, for BALVERSA 4 MG; a $351,988 pharmacy purchase delivery order from VISN 19 on December 16, 2025; and a $359,818 order from VISN 19 on July 18, 2024, for CARVYKTI. Award values per delivery order typically range from $13,600 to $351,988, with nearly all orders carrying firm fixed-price terms and completion dates within thirty days of issuance.
Customer concentration is heavily skewed by vehicle ceiling, not transaction volume. VISN 5 leads by award count with 36 orders totaling $594 thousand, followed by VISN 20 with 11 orders totaling $530 thousand. However, VISN 12 accounts for $10.36 billion in potential value across just four awards — this figure reflects Janssen Biotech's seat on the $6.888 billion multiple-award Federal Supply Schedule (FSS-61-IB) contract awarded September 1, 2024, with an ultimate completion date of August 31, 2029. Janssen Biotech also holds a $15 million single-award Blanket Purchase Agreement awarded September 20, 2024, through September 19, 2026, covering BALVERSA and CARVYKTI. The National Acquisition Center granted the BPA and holds administrative authority; delivery orders flow from regional Veterans Integrated Service Networks.
Activity has grown from 10 awards in 2022 to 22 in 2024, then declined to seven in 2025 (a partial-year count). The most recent award from March 2026 suggests ongoing engagement. Combined potential value across all 107 awards reaches $10.38 billion, though only $3.8 million in dollars has been obligated — the disparity reflects the ceiling values of the two large IDVs, which serve as procurement vehicles for call orders rather than funds reserved. The vendor holds no subcontract relationships; all work is delivered as a prime contractor manufacturing and distributing pharmaceuticals from facilities in Carrollton, Texas, and Horsham, Pennsylvania.
Corporate structure includes two named subsidiaries: Actelion Pharmaceuticals US, Inc. and Janssen Products, LP, both for-profit manufacturers. Janssen Biotech operates as a business unit of Johnson & Johnson's pharmaceutical division, competing for federal work solely through full-and-open GSA schedule and BPA procurements without pursuing set-aside categories. The vendor's federal customer base remains monolithic — the Department of Veterans Affairs is the sole funding federal agency across all recent awards, with no diversification to other agencies or mission areas.
Contract vehicles
Quick answers
What is Janssen Biotech Inc.'s UEI?
Janssen Biotech Inc.'s Unique Entity ID (UEI) in SAM.gov is NVYMGFA53MN7.
What is Janssen Biotech Inc.'s CAGE code?
Janssen Biotech Inc.'s CAGE code is 0MJM1.
What is Janssen Biotech Inc.'s primary NAICS code?
Janssen Biotech Inc.'s primary NAICS code is 325414 (Biological Product (except Diagnostic) Manufacturing).
Where is Janssen Biotech Inc. located?
Janssen Biotech Inc.'s physical address in SAM.gov is 800 Ridgeview Drive, Horsham, PA 19044, USA.
Is Janssen Biotech Inc. registered in SAM.gov?
Yes. Janssen Biotech Inc.'s SAM.gov registration is active through November 21, 2026.
Which contract vehicles does Janssen Biotech Inc. hold?
Janssen Biotech Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Janssen Biotech Inc.'s most recent federal award?
Janssen Biotech Inc.'s most recent federal contract award is Emergency pharmacy carvykti for RMR (36C25926F0310), from Veterans Integrated Service Network 19, on September 3, 2026.
On GovTribe
See Janssen Biotech Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors